Clinical Study

Early Revelation of Leprosy in China by Sequential Antibody Analyses with LID-1 and PGL-I

Figure 1

Antibody responses of leprosy patients in Yunnan Province. Sera from leprosy patients (MB = 34 and PB = 23), healthy household contacts of MB patients (HHC = 22), pulmonary tuberculosis patients (TB = 17), and uninfected controls (NC; 10 from Yunnan and 10 from Beijing) were assessed by ELISA against ND-O-BSA and LID-1. Glycolipid reactivity was assessed by IgM binding, and protein reactivity was assessed by IgG binding, with each sample distinguished by an individual marker.
352689.fig.001a
(a)
352689.fig.001b
(b)